Review

Melatonin in Medicinal and Food Plants: Occurrence, Bioavailability, and Health Potential for Humans

Bahare Salehi 1, Farukh Sharopov 2, Patrick Valere Tsouh Fokou 3, Agnieszka Kobylinska 4, Lilian de Jonge 5, Kathryn Tadio 5, Javad Sharifi-Rad 6,*, Malgorzata M. Posmyk 4,*, Miquel Martorell 7, Natália Martins 8,9,*, and Marcello Iriti 10,*

1 Student Research Committee, School of Medicine, Bam University of Medical Sciences, Bam 44340847, Iran
2 Department of Pharmaceutical Technology, Avicenna Tajik State Medical University, 73400 Dushanbe, Tajikistan
3 Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé Po. Box 812, Cameroon
4 Laboratory of Plant Ecophysiology, Faculty of Biology and Environmental Protection, University of Lodz, 90-237 Lodz, Poland
5 Department of Nutrition and Food Studies, George Mason University, Fairfax, VA 22030, USA
6 Zabol Medicinal Plants Research Center, Zabol University of Medical Sciences, Zabol 61615-585, Iran
7 Department of Nutrition and Dietetics, Faculty of Pharmacy, University of Concepcion, Concepcion 4070386, Chile
8 Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
9 Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal
10 Department of Agricultural and Environmental Sciences, Milan State University, 20133 Milan, Italy

* Correspondence: javad.sharifirad@gmail.com (J.S.-R.); posmyk@biol.uni.lodz.pl (M.M.P.); ncmartins@med.up.pt (N.M.); marcello.iriti@unimi.it (M.I.); Tel.: +98-21-88200104 (J.S.-R.); +48-42-6354422 (M.M.P.); +351-22-5512100 (N.M.); +39-2-5031-6766 (M.I.)

Received: 11 June 2019; Accepted: 3 July 2019; Published: 5 July 2019

Abstract: Melatonin is a widespread molecule among living organisms involved in multiple biological, hormonal, and physiological processes at cellular, tissue, and organic levels. It is well-known for its ability to cross the blood–brain barrier, and renowned antioxidant effects, acting as a free radical scavenger, up-regulating antioxidant enzymes, reducing mitochondrial electron leakage, and interfering with proinflammatory signaling pathways. Detected in various medicinal and food plants, its concentration is widely variable. Plant generative organs (e.g., flowers, fruits), and especially seeds, have been proposed as having the highest melatonin concentrations, markedly higher than those found in vertebrate tissues. In addition, seeds are also rich in other substances (lipids, sugars, and proteins), constituting the energetic reserve for a potentially growing seedling and beneficial for the human diet. Thus, given that dietary melatonin is absorbed in the gastrointestinal tract and transported into the bloodstream, the ingestion of medicinal and plant foods by mammals as a source of melatonin may be conceived as a key step in serum melatonin modulation and, consequently, health promotion.

Keywords: melatonin; bioactive phytochemicals; antioxidants; herbal remedies; tryptophan derivatives; nutraceuticals

1. Introduction

Melatonin is a tryptophan-derived substituted indoleamine (N-acetyl-5-methoxytryptamine; Figure 1), widely found in living, evolutionarily distant organisms [1]. This molecule was isolated in 1958 by Lerner et al. [2] from cow pineal gland. For decades, melatonin was considered an animal...
neurohormone with an impact in circadian rhythm regulation, seasonal reproductive cycles, and mammalian immune system modulation [3,4], but currently these studies are outdated. However, in the 1980s and later, melatonin was also identified in many non-vertebrates (e.g., cnidarians, planarians, mollusks, insects, crustaceans) [5,6], and in 1989, it was detected in a phototrophic unicell, the dinoflagellate Gonyaulax polyedra (current name: Lingulodinium polyedrum) [7], and thereafter analyzed in detail [8]. Subsequently, in 1995, melatonin was identified in some plant species [9,10] and, since then, the interest on this molecule by plant physiologists has rapidly increased. In the 1990s, an essential and novel function was discovered and attributed to this molecule—a highly potent hydroxyl radicals scavenger [11], a finding that was considered the starting point of extensive studies on melatonin antioxidant protection, which turned out to involve numerous mechanisms beyond radical scavenging [12–17].

2. Melatonin in Plants

Nowadays, it is widely recognized that melatonin is a universal amphiphilic antioxidant molecule, able to penetrate all compartments of a cell because of its small size, and good solubility in both water and lipids. Looking at melatonin antioxidant properties, it mainly consists of (1) direct scavenging of reactive oxygen (ROS) and reactive nitrogen (RNS) species [18]; (2) acceleration of antioxidant enzymes activity [19]; (3) protection against oxidative damage [20]; (4) synergistic effects with other antioxidants [21]; and (5) improvement of the electron transport efficiency in mitochondrial respiratory chain, limiting free radicals overproduction through electron leakage reduction [22,23]. Moreover, not only melatonin, but also its derivatives act as natural electron donors, highly efficient against oxidative stress. Melatonin is also able to generate a radical scavenger cascade (Figure 2), originating oxidation products, such as β-hydroxymelatonin, cyclic β-hydroxymelatonin or cyclic melatonin [24], and N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) [25], and to contribute to further ROS elimination [26]. In contrast with other antioxidants, this ability makes melatonin effective in protecting organisms against oxidative stress, even in small doses [27]. Indeed, the maintenance of a proper redox status in aerobic cells (in mitochondria) is the basis for the efficient functioning of their metabolism. Also, it seems to be especially important, when an organism, for example, a plant, has a photosynthetic apparatus (in chloroplasts) that is an extra endogenous source of free radicals and ROS generation.
Since then, the search for this molecule in many edible plants and medicinal herbs has been extensively reported [28–34]. Melatonin has been found inter alia in apple, barley, bean, cucumber, grapes, lupine, maize, potato, rice, and tomato, among others (Table 1) [1,28–31,35–39].

In 1995, two independent papers confirmed the presence of melatonin in higher plants [9,10].

Table 1. Melatonin contents in some plant organs [40].

| Common Name         | Latin Name                          | Organ  | Melatonin [ng g⁻¹ DW] | Reference |
|---------------------|-------------------------------------|--------|-----------------------|-----------|
| Coffee robusta      | Coffea canephora Pier.              | Bean   | 5800                  | [41]      |
| Coffee arabica      | Coffea arabica (L.)                 | Bean   | 6800                  | [41]      |
| Black pepper        | Piper nigrum (L.)                   | Leaf   | 1093                  | [42]      |
| Wolf berry (goji)   | Lycium barbarum (L.)               | Fruit  | 530                   | [43]      |
| White radish        | Raphanus sativus (L.)               | Bulb   | 485                   | [43]      |
| White mustard       | Sinapis alba (L.)                   | Seed   | 189                   | [1]       |
| Black mustard       | Brassica nigra (L.)                 | Seed   | 129                   | [1]       |
| Curcuma             | Curcuma aeruginosa Roxb.            | Root   | 120                   | [43]      |
| Wolf berry          | Lycium barbarum                    | Seed   | 103                   | [1]       |
| Burmese grape       | Baccaura ramiflora Lour.            | Leaf   | 43.2                  | [42]      |
| Fenugreek           | Trigonella foenum-graecum (L.)      | Seed   | 43                    | [1]       |
| Almond              | Prunus amygdalus (Batsch)           | Seed   | 39                    | [1]       |
| Sunflower           | Helianthus annuus (L.)              | Seed   | 29                    | [1]       |
| Fennel              | Foeniculum vulgare (Gilib.)        | Seed   | 28                    | [1]       |
| Agati               | Sesbania glandiflora (L.) Desv.    | Leaf   | 26.3                  | [42]      |
| Bitter melon        | Momordica charantia (L.)           | Leaf   | 21.4                  | [42]      |
| Alfalfa             | Medicago sativum (L.)              | Seed   | 16                    | [1]       |
| Green cardamom      | Elettaria cardamomum (White et Maton) | Seed | 15 | [1] |
| Flax                | Linum usitatissimum (L.)           | Seed   | 12                    | [1]       |
| Linseed (flax)      | Linum usitatissimum (L.)           | Seed   | 12                    | [1]       |
| Java bean           | Senna tori (L.) Roxb.              | Leaf   | 10.5                  | [42]      |
| Sesban              | Sesbania sesban (L.) Merr.         | Leaf   | 8.7                   | [42]      |
| Anise               | Pimpinela anisum (L.)              | Seed   | 7                     | [1]       |

Figure 2. Antioxidant cascade of melatonin derivatives in plants. Melatonin can be hydroxylated at different C-atoms (2, 3, 4, 6, 7, 8) by subsequent interactions with two hydroxyl radicals. ROS, reactive oxygen species; UVB, ultraviolet B (shortwave) rays.
Table 1. Cont.

| Common Name    | Latin Name          | Organ   | Melatonin $[\text{ng} \ g^{-1} \text{DW}]$ (or FW*) | Reference |
|----------------|---------------------|---------|--------------------------------------------------|-----------|
| Celery         | Apium graveolens (L.) | Seed    | 7                                                | [1]       |
| Coriander      | Coriandrum sativum (L.) | Seed    | 7                                                | [1]       |
| Poppy          | Papaver somniferum (L.) | Seed    | 6                                                | [1]       |
| Walnut         | Juglans regia (L.)   | Seed    | 3.5                                              | [44]      |
| Milk thistle   | Silphium marianum (L.) | Seed    | 2                                                | [1]       |
| Sweet cherries | Prunus avium (L.)    | Fruit   | 120*                                              | [45]      |
| Tart cherries  | Prunus cerasus (L.)  | Fruit   | 19.5*                                             | [46]      |
| Grapevine      | Vitis vinifera (L.)  | Fruit   | 18*                                              | [47]      |
| Cherry         | Prunus cerasus (L.)  | Fruit   | 18*                                              | [46]      |
| Corn           | Zea mays (L.)        | Seed    | 14-53*                                            | [24]      |
| Cucumber       | Cucumis sativus (L.) | Seed    | 11-80*                                            | [24]      |
| Strawberry     | Fragaria x ananassa (Duch.) | Fruit | 11.3*                                             | [48]      |
| Pomegranate    | Punica granatum (L.) | Fruit   | 5.5*                                             | [49]      |
| Tall fescue    | Festuca arundinacea  | Seed    | 5.3*                                             | [10]      |
| St. John’s wort| Hypericum perforatum (L.) | Flower | 4*                                              | [50]      |
| Lupine         | Lupinus albus (L.)   | Seed    | 3.8*                                             | [36]      |
| Tomato         | Solanum lycopersicum (L.) | Fruit | 2.5*                                              | [51]      |
| Fever few      | Tanacetum parthenium (L.) | Leaf | 2*                                              | [50]      |
| St. John’s wort| Hypericum perforatum (L.) | Leaf | 2*                                              | [50]      |
| Oat            | Avena sativa (L.)    | Seed    | 1.8*                                             | [10]      |
| Corn           | Zea mays (L.)        | Seed    | 1.4*                                             | [10]      |
| Grapevine      | Vitis vinifera (L.)  | Fruit   | 1.2*                                             | [52]      |
| Rice           | Oryza sativa japonica (L.) | Seed | 1*                                              | [10]      |

* corresponds to FW. DW, dry weight; FW, fresh weight.

Studies in 108 herbs species, commonly used in Chinese Medicine, revealed the presence of melatonin at concentrations ranging from a few to several thousand nanograms per gram of tissue [43], meaning that they are good natural sources of this health-related molecule. Melatonin was also detected and quantified in roots, shoots, leaves, flowers, fruits, and seeds, but its highest levels have been found in reproductive organs, particularly in seeds. This abundance is probably related to the impact of reproductive organs in plant species survival, and to their need to effectively defend them against various environmental stresses, including secondary oxidative stress [1,24]. On the other hand, it was also stated that melatonin concentrations differ not only among species, but also among different varieties of the same species [31]. Thus, it has been suggested that variations in melatonin contents might result not only from the distinct extraction and detection techniques applied, but also from the fact that both the biosynthesis and metabolism of this indoleamine are affected and modified by distinct environmental conditions [51]. This aspect partially explains why different organs of the same plant contain various amounts of melatonin during consecutive morphological and physiological stages of development. Generally, it was noticed that various plant species rich in melatonin has a greater capacity of stress tolerance [53–56], an aspect that turned attention to melatonin as a potentially effective agent in improving plant stress defense. Moreover, exogenous melatonin can also be used as a crop biostimulating agent [57–59].

In scientific literature, the term phytomelatonin sometimes appears, which is mostly applied to distinguish the endogenous melatonin synthesized by plants from the exogenous one, applied to them, although chemically, the molecule is the same. Not least interesting to highlight is that, in medicinal plants, including pyrethrum maruna (Tanacetum parthenium L.) and St. John’s wort (Hypericum perforatum L.), the levels of melatonin are sometimes higher than those found in animals [50], although both organisms possess the required enzymatic systems for melatonin biosynthesis (Figure 3). Moreover, and contrarily to animals, plants are also able to synthesize the melatonin precursor, tryptophan, an aromatic amino acid. Theoretically, it is constantly available for further transformations in plants, while in animals, it can only be supplied by foods. Still, and besides its in vivo synthesis, plants can also absorb
melatonin provided exogenously from the environment, accumulating it at high concentrations \[24,60\]; thus, they can be conceived as great sources of melatonin and other indoleamines for animals.

**Figure 3.** Comparison of melatonin biosynthetic pathways in plants and humans. AADC, aromatic-l-amino-acid decarboxylase; AANAT, arylalkylamine N-acetyltransferase; ASMT, N-acetylserotonin methyltransferase; COMT, caffeic acid O-methyltransferase; HIOMT, hydroxyindole-O-methyltransferase; SNAT, serotonin-N-acetyltransferase; T5H, tryptamine 5-hydroxylase; TDC, tryptophan decarboxylase; TP5H, tryptophan 5-hydroxylase \[61\].

Regarding melatonin biosynthetic pathways, they are similar between animals (humans) and plants (Figure 3). Briefly, they consist of the same precursor, tryptophan, and two common derivatives, serotonin and N-acetyl-serotonin. However, the tryptophan conversion to serotonin in animals occurs via 5-hydroxy-tryptophan, whereas in plants, it occurs via tryptamine. In the latter, serotonin can be converted into melatonin via N-acetyl-serotonin (as in animals) and 5-methoxy-tryptamine \[62–64\]. Thus, it is feasible to suppose that indole derivative transformations in plants are richer and multidirectional when compared with animals.

In all organisms, the primary function of melatonin is to act as a free radical’s scavenger and ROS detoxifying agent. These reactive species are highly generated during the aerobic metabolism, mainly in mitochondria and chloroplasts; thus, it has been hypothesized that these organelles are sites of melatonin biosynthesis in plants \[45\]. Indeed, it is believed that archaic purple non-sulphur bacteria (i.e., *Rhodospirillum rubrum*) and photosynthetic cyanobacteria after ingestion by primer eukaryotes eventually transformed via endosymbiosis into mitochondria and chloroplasts, respectively, or more advanced eukaryotes. According to the hypothesis of Tan et al. \[45\], in most organisms, if not all, the capacity of melatonin biosynthesis may have been transferred from mitochondria and chloroplasts to other cell compartments, such as endoplasmic reticulum and cytosol. In fact, during evolution, involved genes in melatonin biosynthesis found in *R. rubrum* or other non-sulphur purple bacteria and cyanobacteria were gradually integrated into the nuclear genome, although some of
them may have also been lost [65]. Anyway, it seems that the hypothesis related to the original location of melatonin biosynthesis in mitochondria and chloroplasts may help in answering the question of why the melatonin content in green plants is markedly higher than in animals. Moreover, the contributory factor in explaining this phenomenon seems to be related to the presence of two organelles (mitochondria and chloroplasts) able to synthesize melatonin in plants in comparison to animals, which have only mitochondria.

Taking a look at the predicted protective effect of melatonin on plant photosynthesis, it has also been confirmed [66,67]. Broadly, melatonin affects photosynthetic processes efficiency by the following: (1) delaying chlorophylls degradation [68,69]; (2) increasing CO₂ uptake [70,71]; and (3) accelerating the electron transport [72,73]. However, besides its direct and indirect properties against oxidative damage, which is secondary to all abiotic and biotic stresses, melatonin also stimulates a number of specific plant defense mechanisms at the proteomic [74,75] and genetic [55,76,77] levels, against various stresses, like cold, drought, high temperatures, strong light, heavy metals, and pathogens, among others.

As a structural analog of indole-3-acetic acid (IAA), a common auxin also derived from tryptophan, melatonin, is involved in plant growth regulation and development [33,34,78]. There are also earlier reports that indicate the role of melatonin in plant circadian rhythm regulation and photoperiodic responses; however, to precisely explain these phenomena requires further investigations [23]. The studies on melatonin in plants indicate that it is a very important molecule for them. Although it is not classified as a phytohormone, melatonin does perform crucial signaling functions at a multilevel metabolic network, especially in plant–environment interactions [79]. Thus, as melatonin was identified in a huge number of edible plants and herbs, its presence in food products and beverages derived from plants is not surprising. Various beverages, for example, beer, coffee, red wine, and several types of tea [31], as well as olive and mustard oil [80], have been studied as potential natural sources of this indoleamine.

3. Melatonin in Humans: A Key Emphasis in Biological Activity

Circadian clocks have developed to adapt biological functions to specific times within the day or night [81]. This clock controls diurnal sleeping and waking cycles, body temperature, and hormone release. Suprachiasmatic nucleus (SCN) cells receive neural cues from the retina and send the information obtained on photoperiodic status to the pineal gland, which then synthesizes them and releases melatonin, distributing the time signal to the rest of the body [82].

With concerns to melatonin biosynthesis in humans, the exogenous amino acid tryptophan through the action of tryptophan hydroxylase (TPSH) and aromatic acid decarboxylase (AADC) enzymes is converted to the neurotransmitter, serotonin. In the subsequent step, serotonin is converted into melatonin through the influence of arylalkylamine N-acetyltransferase (AANAT) and hydroxyindole-O-methyltransferase (HIOMT) enzymes (Figure 3) [83].

Melatonin synthesis proceeds for 24 h/day. However, more is produced and released into the blood at night. In an adult human, approximately 30 µg of melatonin is synthesized per day, and the maximum concentration in the blood is reached at the mid-dark period. There is no storage of melatonin in the pineal gland; it is released into the bloodstream and then rapidly degraded in the liver [84]. The liver hydroxylates melatonin in the C6 position under cytochrome P450 monooxygenases A2 and 1A action, which is then converted to the sulfate derivative, a 6-sulfatoxymelatonin, which is removed from the body through urine [85].

In the circulatory system, melatonin may be bound to albumin and hemoglobin [84], but it is primarily transported by the serum albumin. The amphiphilic nature of melatonin allows it to easily cross cellular and morphophysiological barriers, including the blood–brain barrier [86]. It was shown, using 2-dimensional X-ray diffraction measurements, that melatonin can reorganize the lipid membranes, with the final effects depending on its concentration. Thus, at low concentrations, the presence of melatonin-enriched patches was observed in the cell membrane, while at high
concentrations, a highly ordered uniform melatonin structure throughout the membrane became apparent. In fact, understanding this phenomenon could help explain the molecular basis of melatonin’s actions, such as its anti-amyloidogenic in the brains of Alzheimer’s disease (AD) patients [87], antioxidant and photoprotective actions, as well as the fact that melatonin so easily penetrates into different cell compartments [88]. Moreover, in mammalian cell transport systems, GLUT/SLC2A and PEPT1/2 were shown to have an active role in facilitating melatonin transport across membranes, especially into mitochondria [14].

Some studies report that foodstuffs intake containing melatonin may contribute to raising the level of this molecule in the serum and 6-sulfatoxymelatonin concentrations in urine [89]. Melatonin produced by many organs, including pineal gland, retina, gastrointestinal tract, skin, lymphocytes, and bone marrow [90], and possibly in every organ, it is also effectively taken from foodstuffs rich in this molecule [15].

As an endogenous indoleamine, melatonin has huge physiological functions, including regulation of the sleep promotion, circadian rhythms, mood, immunomodulatory actions, neuroprotective effects, bone growth, hormonal regulation, tumor suppression, defense against oxidative stress, and anti-inflammatory activity [91]. It may also be considered a therapeutic alternative to fighting bacterial, viral, and parasitic infections [91]. Generally, melatonin is not toxic and is safe; even in extreme doses, only mild adverse effects in a few individuals, such as dizziness, headache, nausea, and sleepiness, have been reported [92]. Although, because of a lack of studies, the intake of exogenous melatonin in pregnant and breastfeeding is not recommended. The main roles and functions of melatonin are presented in Figure 4. Not least important to highlight is that melatonin production in humans decreases with age (i.a., it is already depressed in women during menopause) and it seems to be especially depressed in certain diseases, such as in AD, cardiovascular disorders, and certain malignancies. Also, a reduced melatonin output has been linked to insomnia in older patients and a higher prevalence of cancer [93].

![Figure 4. The main roles and functions of melatonin in humans.](image-url)

### 3.1. Regulation of the Circadian Rhythm, Biological Clock, and Sleep/Wake Cycle

One of the earliest known functions of melatonin is its impact on circadian rhythms’ regulation. Light is the environmental factor known to affect melatonin secretion. Melatonin acts directly on the SCN and modulates clock function. Circadian signals from the SCN are transmitted to the pineal gland via a multi-synaptic pathway, which involves the neural projections from the SCN to the paraventricular nuclei (PVN), the intermediolateral cell column of spinal cord (IML), superior cervical ganglion (SCG), and finally to the pineal gland (SCN → PVN → IML → SCG → pineal gland) [94]. The pineal gland is located in the midline of the brain. It transduces light and dark information to the entire body when it
releases melatonin [95]. The behavioral effect of this information is a result of the specific evolutionary habits of the species. For instance, in humans, the night is a time of sleep, where melatonin promotes it and also depresses body temperature at night [96], while in many other species (e.g., wolf or owl), the nocturnal peak of melatonin secretion is associated with wakefulness and high activity.

3.2. Melatonin Receptors

Melatonin has specific receptors and intracellular targets in different cell types in animals to regulate many physiological functions, through modification of adenylate cyclase, guanylate cyclase, and phospholipase C activities, and membrane channels for calcium and potassium mediate melatonin signaling [97]. Specifically, the MT1 (high affinity) and MT2 (low affinity) melatonin receptors are G-protein-linked [98], and affect protein kinase activity through inhibition of adenylyl (cAMP) and guanylyl (cGMP) cyclase, respectively. These receptors regulate ion flux inside the cell via activation phospholipase [97]. Melatonin receptor 3 (MT3) is probably a quinone reductase 2 (QR2). This enzyme has an important role in free radicals’ neutralization in the organism [99]. However, MT3 receptors have not yet been found in humans, although they are expressed in various tissues of hamsters and rabbits [100]. Also, a putative nuclear receptor is the retinoid Z receptor α (RORα/RZR), though its function is still unclear [101].

Melatonin receptors are widely distributed in the body. They exist in cardiovascular, immune and endocrine systems, reproductive and gestational tissues, and even in the skin and gastrointestinal tract [100]. GPR50, a melatonin-related receptor, has also been identified and is detected in various brain structures and peripheral tissues in humans [102,103].

3.3. Receptor-Mediated Activities

Many of melatonin’s actions are mediated through an interaction with the G-protein coupled membrane-bound melatonin receptors MT1 and MT2, the quinone reductase II enzyme (MT3), or indirectly via nuclear orphan receptors of the RORα/RZR family [100].

Previous studies have shown that melatonin improves induced pluripotent stem cells’ (iPSCs’) proliferation and differentiation into neurons through activating phosphatidylinositide 3 kinases (PI3K)/AKT signal pathway, through modulation of MT1 and MT2 membrane receptor [104]. Moreover, melatonin is effective in treating periodontitis, mucositis, and even some cancers. Melatonin has promising antineoplastic potential owing to its antiproliferative, cytostatic, antimetastatic, and proapoptotic effects against tumor cells [105]. It enhances osseointegration and bone regeneration [76]. The ubiquitin-proteasome system controls osteoblasts and osteoclasts proliferation by providing a mechanism for regulating proteins recirculation. Also, melatonin interacts with the ubiquitin-proteasome system, thus contributing to bone regeneration regulation [106].

Melatonin, an ubiquitously-acting molecule, also regulates hormones’ release, especially those involved on seasonal reproduction and preservation of gamete quality. It inhibits the release of prolactin, luteinizing hormone, and stimulating follicle hormone during seasonal reproductive quiescence. A large body of experimental evidence indicates that melatonin has beneficial effects on reproduction in both male and female animals. In male reproduction, it regulates the following: (1) secretion of two key neurohormones, gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH), through binding to specific receptors and inhibition of both GnRH and LH production; (2) synthesis of testosterone and testicular maturation; and (3) prevention of testicular damage induced by environmental toxins or inflammation [107]. Also, experimental data demonstrated that melatonin increases the maternal-to-zygotic transition (MZT)-related genes expression in vitrified-warmed mouse MII oocytes [108].

In the recent past, several studies have highlighted the location of MT1 and MT2 receptors in different regions of the brain and retina. This has led to the manipulation of these anatomic sites specific to the disease processes [109]. MT1 and MT2 receptors have been found in all layers of the neural retina and the retinal pigmented epithelium. Melatonin protects skin cell against UV damage and regulates
Melatonin is a compound with sufficient therapeutic benefits to prevent cardiovascular diseases [85,99]. It contributes to the cardioprotective effect of lethal ischemia-reperfusion injuries [110], and this effect is in part mediated by the activation of the tumor necrosis factor alpha (TNFα) and signal transducer and activator of transcription 3 (STAT3), which both play a key role in enhancement of the pro-survival the SAFE (survivor activator factor enhancement) pathway for cardioprotection [99].

Melatonin may also be beneficial in the treatment of dopamine-related disorders. Evidence suggests that it modulates dopaminergic pathways involved in the coordination of body movement disorders in humans [111]. Also, melatonin inhibits insulin release from β-cells in the pancreas. There is also an interrelationship between melatonin and insulin in type 1 diabetic (T1D) and type 2 diabetic (T2D) rats and humans. The effects of melatonin on insulin secretion may involve melatonin receptors (MT1 and MT2), inhibiting the adenylyl cyclase (AC)/cyclic AMP system [112]. Thus, melatonin may be promising in diabetes management via the above-mentioned processes.

3.4. Nonreceptor-Mediated Effects

At the whole, redox status plays an essential role in many cellular processes. ROS and RNS overproduction (generate oxidative and/or nitrosative stress) affects several biomolecules, including lipids, proteins, and DNA, consequently triggering some serious diseases, such as cancer, diabetes, and neurological and cardiologic disorders [113–115]. Melatonin is a highly effective ROS eliminator and exhibits numerous protective actions against oxidative stress, and is even reported to be 10× more powerful than vitamin E in scavenging ROS/RNS [116]. Melatonin receptor-independent actions include excessive ROS and RNS neutralization, generated as a result of UV and ionizing radiation, heavy metal toxicity, drugs and alcohol toxicity, and so on. Melatonin’s main metabolites include cyclic 3-hydroxymelatonin and N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) [117]. Figure 5 illustrates melatonin’s antioxidant cascade reactions in mammals [118].

**Figure 5.** Interaction of melatonin with oxidizing agents in humans.

Melatonin protects the brain via the immune system, and as a defense against ROS/RNS damages. It has beneficial effects against mitochondrial dysfunction [119], considered a major causative agent in neurodegenerative diseases, such as AD, Huntington’s disease (HD), and Parkinson’s disease (PD) [85,120,121]. Some studies indicate that melatonin in the range of 50–100 mg/day is effective in reducing oxidative mitochondrial dysfunction in experimental models of AD, HD, and PD. It is equally effective, in vitro and in vivo, in preventing oxidative/nitrosative stress-induced mitochondrial

skin pigmentation. It also has protective effects on retinal pigment epithelial cells, photoreceptors, and ganglion cells. Moreover, when melatonin interacts with calmodulin, it directly antagonizes calcium ions binding to calmodulin [102].
dysfunctions [85]. Lipid peroxidation and ROS/RNS generation in neurons also lead to neuropsychiatric and neurodegenerative disorders; thus, because of the strong antioxidant activity and diverse pleiotropic actions of melatonin, it has been proposed an effective neuroprotective agent in diverse neuropsychiatric disorders [122].

Recently, melatonin has been proposed as a potent mitochondrial protector [14,123]. Indeed, melatonin was detected at higher concentrations in mitochondria than in other organelles or subcellular compartments. To highlight that, mitochondria comprise the major cellular site of ROS production during respiration and adenosine triphosphate (ATP) synthesis. In addition, high levels of melatonin are accumulated in these organelles against a concentration gradient by mitochondrial membrane transporters. Not least important to highlight is that, according to the endosymbiotic theory on the origin of mitochondria from melatonin-producing bacteria, these organelles likely evolutionarily inherited the capacity to synthesize melatonin. Therefore, as recently reported in excellent reviews, melatonin can scavenge ROS, thus decreasing mitochondrial oxidative damages, consequently preserving their structural and functional integrity, and finally delaying cellular aging and the onset of age-related disorders [13,123].

Melatonin also possesses anti-inflammatory and anti-apoptotic properties. It protects cells against damage and improves cell survival and proliferation [124]. Further, melatonin, owing to its low toxicity and high efficacy in reducing oxidative damage, has been recommended as a protective candidate against typical chemical weapons [125] and even as a snakebite therapy [126].

As an anti-inflammatory molecule, melatonin differentially modulates pro-inflammatory enzymes; controls inflammatory mediators’ production, such as cytokines and leukotrienes; and regulates leukocytes lifespan through interfering with apoptotic processes. Indeed, it selectively inhibits inflammation by stimulating pro-inflammatory mediators, such as arachidonic and 5-hydroxyeicosatetraenoic (5-HETE) acids, through phospholipase A2 (PLA2) and 5-lipoxygenase (5-LOX) activation, respectively [83].

The experimental evidence has yielded promising results regarding the role of melatonin as an anti-carcinogenic agent [105]. It is beneficial in preventing and treating several common cancers [127]. Indeed, melatonin appears to promote apoptotic death in some cancer cells, while being protective to normal cells [107]. Melatonin has cytoprotective properties in the reproductive system by reducing apoptosis of the oocyte and granulosa cells [86]. Melatonin also inhibits the hypoxia-inducible factor 1 alpha (HIF-1α) and HIF-1α-inducible gene [128].

In conclusion, melatonin has attracted the attention of many scientists owing to its unique physiological functions and pharmacological properties. In the last decade, hundreds of scientific publications have focused on melatonin. It is a regulatory molecule that orchestrates a variety of physiological and pathophysiological processes. Beneficial effects of melatonin in various models of disease provide support/robustness for the general comment that “melatonin helps against everything” [129]. Melatonin is used by millions of people around the world to potentially retard aging diseases, improve sleep, mitigate jet-lag symptoms, and treat depression [130], besides being a safe, cheap, natural, and widely available molecule with multiple therapeutic benefits.

4. Melatonin Supplementation and its Health Effects for Humans

Individuals living in highly industrialized countries look for melatonin-supplemented drugs and pills as a way to improve sleep and rest, as the main advantages include quicker times to fall asleep and quicker “jet-lag” reductions. On the other hand, some of the users also referred to experience headaches, dizziness, and sleepiness during daylight hours (overdose symptoms), but these made be placebo effects [96]. Initially, many studies have shown that exogenous melatonin was able to improve sleep, probably because of the chronobiotic role of this molecule. Indeed, it aids in the adjustment and maintenance of a regular circadian rhythmicity [131]. However, there are many other potential health effects attributed to melatonin’s application. For example, melatonin supplementation is helpful in inflammatory markers, hypertension, oxidative stress, and metabolic syndrome [132]. In one of
these studies, a positive correlation was found between melatonin-rich foods and clinical-metabolic indicators. Also, melatonin concentration varies markedly among various foods, and its concentration may change during the food products' preparation [133].

4.1. Melatonin and Inflammation

Melatonin inhibits cyclooxygenase-2 (COX-2), the enzyme responsible for the inflammatory cascade. Moreover, melatonin decreases pain perception during the inflammatory response, but may also enhance the analgesic effects of nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen [134]. In 2002, El-Shenawy and coworkers determined the mechanism of anti-inflammatory and anti-nociceptive (sensory nervous system response to pain) effects of melatonin [135]. For that, the authors injected carrageenan (1%) into the rats’ paw to induce inflammation. Rats either received a diluent or melatonin 30 min pre-injection and they analyzed its potential for paw edema at 1, 2, 3, and 4 h post-carrageenan injection. Paw thickness aided in determining the inflammation level and edema formation. Nociception was tested based on rat vocalization after electrical stimulation of the tail. Melatonin, given intraperitoneally to rats 30 min before the carrageenan injection, was found to decrease swelling of the paw induced by the toxin. At doses of 0.5 and 1 mg/kg, melatonin was found to inhibit carrageenan-induced edema in 20.5% and 29.6%, respectively, when compared with the control at 4 h post-carrageenan injection. Melatonin at both 0.5 and 1 mg/kg also exerted anti-nociceptive effects on electrical stimulation in the rat trail test, and the increase in nociceptive thresholds to pain brought on by the electrical pain at 4 h post-treatment was 29.6 and 39.6%, respectively. When melatonin was given in combination with a COX-1 and COX-2 inhibitor, indomethacin (5 mg/kg, i.p.), 30 min in advance of carrageenan injection, the anti-inflammatory effects were enhanced by 23% in the paw edema model. A higher melatonin dose (5 mg/kg) further increased the anti-nociceptive effects of indomethacin. Anti-inflammatory and anti-nociceptive effects of the COX inhibitor slightly increased with 0.5 mg/kg melatonin. Also, it was also observed that melatonin elevates the cysteamine (300 mg/kg, s.c.) effect in the carrageenan-induced rat paw edema model. No anti-inflammatory effects were found using melatonin doses of 20 and 40 µg per paw. On the basis of the results, the authors concluded that melatonin has anti-inflammatory and anti-nociceptive effects in rats and may enhance the action of indomethacin [135].

4.2. Melatonin and Wound Repair

Melatonin promotes the immune system response early in the wound healing process and may even aid in healing and scar formation quality. In the study of Pugazhenthi et al. [136] with male rats, a positive correlation between superficial application of melatonin and scar repair was noted. Melatonin acts as a strong anti-inflammatory agent, also having positive immunomodulatory effects under certain conditions. In the cited study, a melatonin injection (1.2 mg/kg) into subdermal tissue in rats was examined for its ability to inhibit scar formation after an incision made in the skin. Melatonin treatment improved the scars’ quality by modulating their maturity rate and orientation of the collagen fibers. Moreover, melatonin depressed nitric oxide (NO) synthesis during the inflammatory process. In addition, while NO is generally detrimental during inflammation, it has positive effects during new tissue formation [136]. The subdermal injection of melatonin also expedited the angiogenic process, through intensifying the new blood vessel formation and increasing the vascular endothelial growth factor (VEGF) protein expression in granulation tissue formation. An increase in arginase levels, the enzyme that plays a crucial role in proline biosynthesis [136], was similarly observed. This amino acid is a factor determining a protein’s quaternary structure, and is very useful during collagen synthesis and its spatial conformation. This study documents that melatonin, when added under the epidermis, might be beneficial in improving incision healing and in reducing scar formation.
4.3. Melatonin and Brain Injury

Brain injury, as a result of stroke and trauma, readily interferes with neurological functions. In brain injury, inflammation and oxidative stress are commonly involved. Many brain traumas result in a change in blood flow, which leads to hypoxia. In addition, hypoxia may paradoxically lead to the so-called “oxygen burst”, which means its incomplete reduction and generation of ROS and free radicals, which in turn damages cell membranes and impairs cognitive function [137,138]. Melatonin is also a highly effective antioxidant, free radical scavenger, and anti-inflammatory agent with therapeutic effects on brain injuries [139–141]. Treatment with melatonin over 30 days in mice with induced stroke led to a marked improvement in brain cell survival and functional recovery. Several studies have correlated melatonin administration with the long-lasting improvement of motor and coordination physiology, which are also common in human strokes [142]. Melatonin levels often drop in patients who have suffered a severe brain injury, and animal studies have concluded that replenishing melatonin levels after the injury helps to reduce tissue injuries and also decrease cognitive deficits [143]. Melatonin also aids in toxic ROS reduction, produced when brain cells are deprived of oxygen, and likewise reduces the inflammatory systems activation in the brain; these changes are essential in aiding infant size post-head injury reduction [144]. Melatonin also has a positive impact on memory deficits when immediately administered after rabbits experience a brain injury [145]. Melatonin also protects fetal animals’ brains against ischemia/repulsion injury when it occurs during pregnancy [146]. In human pregnancies, similar injuries may result in cerebral palsy or mental retardation in newborn infants. Melatonin has been found to prevent learning disorders correlated with brain injuries in infant animals, and repeated doses have exhibited a further reduction in brain injury [123]. In fact, numerous reports have confirmed that melatonin supplementation has strong abilities to protect the brain against injury.

4.4. Melatonin and Cardio- and Neuro-Protection

Melatonin also increases the antioxidant enzymes’ activity and also scavenges free radicals produced during cardiac injury. Because of its direct and indirect antioxidant properties, melatonin prevents oxidative damage and reduces the size area of heart cell death [147]. Moreover, melatonin stimulates antioxidant enzymes, while simultaneously down-regulating the pro-oxidant enzymes. Its administration has also been shown to be effective in reducing hypertension and drugs-induced cardio-toxicity [147,148]. Moreover, when myocardial infarction (MI) was induced in rats, melatonin administration (4.5 mg/kg/day) post-MI (via subcutaneous osmotic pumps) significantly lowered the left ventricular (LV) levels of mRNAs, dihydropyridine receptor (DHPR), ryanodine receptor 2 (RYR2), and sarco-endoplasmic reticulum Ca²⁺-ATPase (SERCA2) compared with these measures in control rats. These authors concluded that melatonin improved the strength of the heart’s pumping action post-MI under these experimental conditions [96]. Reiter and Tan [147] have also noted that melatonin protects mitochondria, which is the energy source for cardiac muscle function.

Research focused on the protective role of melatonin in the degree of cardiac injury in patients undergoing bypass surgery, in 45 patients (45–65 years old), reported that melatonin (10 mg or 20 mg capsule once daily) increased the ejection fraction associated with a significant decline in heart rate [149]. In addition, melatonin significantly reduced plasma levels of troponin-I, interleukin-1beta, inducible oxide synthase, and caspase-3 enzymes, in both supplemented groups. The authors concluded that melatonin supplementation can ameliorate the degree of myocardial ischemic-reperfusion injury. Also, a study focusing on melatonin effects in 97 normotensive and hypertensive volunteers (63–91 years old) found that melatonin supplementation (1.5 mg/day for two weeks) had a direct hypotensive effect [150]. Also, melatonin stabilized the internal temporal order, enhancing the circadian component and the synchronization between rhythms of different physiological functions.

On the other hand, melatonin administration has also been shown to be useful to improve the cognitive performance in subjects with mild cognitive impairment (MCI) [151]. Each year, about 12% of MCI patients eventually develop AD or other types of dementia. In a study of 25 MCI patients, who received 3–9 mg of melatonin before sleep over 8–9 months exhibited better performance in the
Mini-Mental State Examination and a cognitive subscale of AD assessment. The authors also reported that melatonin-supplemented patients had better scores on Rey’s verbal tests, Trail A and B tasks, and Mattis’ test, but the treatment did not affect the Digit-symbol test score. Finally, it was found that abnormally high Beck Depression Inventory scores decreased in melatonin-treated patients. Thus, these studies suggest that melatonin may be useful in the treatment of MCI patients [151].

The use of melatonin to treat neurodegenerative diseases revealed that this molecule was able to reduce amyloid-beta peptide (Aβ) deposits in the brains of AD patients [87]. This finding indicates that activated glia due to chronic inflammation correlates with Aβ deposits in the brains of AD patients. In this study, melatonin effects were specifically examined on glia activation and an increase in learning in amnesic rats, induced by Aβ peptide 25–35, was observed. Cognitive function was analyzed using the Morris water maze test. The study reported that Aβ 25–35 injected into the rat hippocampus promoted impairments in learning and memory, which was associated with a rise of activated glial cells compared to controls. When melatonin was administered at 0.01, 0.1, and 1 mg/kg over 10 days, learning and memory improved in rats that had received the Aβ 25–35. Melatonin inhibited pro-inflammatory factors in these animals, and when applied to humans, it may aid in the treatment of AD patients with regards to memory and learning improvement [87].

A report by Kilic et al. [152] was conducted to identify the potential positive effects of melatonin in amyotrophic lateral sclerosis (ALS). ALS is a disease that involves oxidative stress in alpha-motor neurons of the spinal cord. The authors observed that melatonin is a possible neuroprotective compound and strong antioxidant in this disease model. Experiments were done with different test models: (1) in cultured motoneuronal cells (NSC-34); (2) in a genetic mouse model of ALS [SOD1 (G93A)-transgenic mice], and (3) in a group of 31 patients with sporadic ALS. Melatonin decreased glutamate-induced cell death in cultured motoneurons. In SOD1 (G93A)-transgenic mice, high melatonin doses administered post-poned disease advancement orally and increased survival. Also, ALS patients receiving a high dose (300 mg/day) of rectal melatonin over the course, over two years, were found to have normalized levels of protein carbonyls (an oxidative stress marker) in circulation. The authors concluded that high melatonin doses are safe for humans and it is suitable for clinical trials to gain information on its effect as an antioxidant in ALS patients [152].

5. Oral Bioavailability of Plant Melatonin

Exogenously administered melatonin is well absorbed following oral administration, widely distributed, and virtually completely metabolized in humans [153]. Melatonin receptors are abundant in the brain and melatonin readily penetrates the blood–brain barrier [154]. Melatonin, when consumed as a drinking fluid [155] or taken as a galenic tablet [156], is readily absorbed into circulation. Thus, it would be expected that melatonin from foods would also likely be absorbed. While this may be true, melatonin uptake from herbal remedies or products, and phytomelatonin oral bioavailability, have not been well explored.

The study of Yeleswaram et al. [157], assessing the oral bioavailability of synthetic melatonin in rats, dogs, and monkeys, showed a dose-dependent availability that differed among the species examined. The dose normalized oral bioavailability following a 10 mg/kg oral dose of melatonin represented 53.5% in rats, while it was around 100% in dogs and monkeys. However, the oral bioavailability of melatonin in dogs was found to be decreased to 16.9% following a 1 mg/kg oral dose. In vitro permeability studies with CACO-2 cells, the model suggested that exogenous melatonin is likely to be well absorbed in humans [157]. Hattori et al [10] investigated the oral melatonin bioavailability from 24 edible plants and found that the administration of a diet consisting in plant products rich in melatonin to 48 h fasted chicks significantly increased the level of circulating melatonin, that is, the daytime melatonin levels were roughly doubled. Moreover, they found that competes with melatonin binding sites in the rabbit brain [10].

Melatonin absorbed into feed pellets or into wheat grains that received chicken food also led to its high initial plasma melatonin concentration, followed by a rapid decrease after 2–3 h; however,
elevated levels were still detectable up to 24 h after administration. While melatonin absorbed into cracked wheat grains subsequently washed with ethanol eliminated the initial transitory peak, it sustained the plasma levels for at least 12 h in the normal nocturnal range (750 pM), and there was no measurable melatonin increase (<60 pM) 18 h later. The authors concluded that melatonin-treated, ethanol-rinsed cracked wheat grains could be used to experimentally mimic the long-night plasma melatonin patterns [158].

Food restriction of rats and then feeding them with regular chow or melatonin-rich (3.5 ng/g FW) walnuts (*Juglans regia* L.) was followed by elevated blood melatonin concentrations in animals that had eaten walnuts (increased from 11.5 to 38.0 pg/mL), compared with rats fed the control diet. Increases in blood, melatonin were also accompanied by rises in serum antioxidant capacity [44]. However, it is unclear whether other plant components can trigger or reduce the release or uptake of melatonin into the gastrointestinal tract or organs involved in metabolism, such as liver [159].

Similar experiments with rats were performed by Aguilera et al. [160], but as a source of phytomelatonin, they used bean (*Phaseolus vulgaris* L.) sprouts, that is, the aqueous extract from bean sprouts. The authors assessed in rats the effect of bean sprout intake on plasma melatonin levels and its metabolite, 6-sulfatoxymelatonin, in urine. Also, they compared the bioavailability derived from bean sprouts versus synthetic melatonin. Blood and urine samples were obtained before and after 90 min of melatonin (phyto- or synthetic) administration via a gavage. The plasma melatonin levels increased after bean sprout ingestion (16%, *p* < 0.05). This increment correlated with the urinary 6-sulfatoxymelatonin content, the principal biomarker of plasma melatonin levels (*p* < 0.01). In contrast to the previous discussed findings by Reiter, Manchester, and Tan [44], the antioxidant capacity did not exhibit any significant change. The comparison of bioavailability between bean sprouts phytomelatonin and synthetic melatonin indicated slightly higher levels of plasma melatonin (17%) in rats fed with the synthetic melatonin solution [160].

**Melatonin Oral Bioavailability in Humans**

When looking at melatonin bioavailability, a number of studies already performed report an extensive variation, even assessing its oral and/or intravenous administration. In addition, and not least interesting to highlight, is that considerable variations in melatonin aspects related with its absorption, metabolism, and elimination have also been stated between distinct individuals. These aspects clearly reflect the need for more in-depth studies on the pharmacokinetic properties of melatonin. For instance, Andersen et al. [161] conducted a crossover cohort study to determine the pharmacokinetics of 10 mg oral melatonin or 10 mg intravenous melatonin in healthy male volunteers. Orally administered melatonin was rapidly absorbed, with *T*<sub>max</sub> being reached at 41 min; however, the *C*<sub>max</sub> and the area under the curve (AUC) varied significantly among volunteers. With regards to oral and intravenous melatonin elimination half-lives, they were 54 min and 39 min, respectively. Thus, oral melatonin bioavailability was found to be only 3% with considerable inter-volunteer variability.

The physiological changes in human plasma melatonin have also been investigated after beer consumption. Eighteen brands of beer containing melatonin up to 170 pg/mL were analyzed. Beer administered to seven subjects consisting of four men (660 mL) and three females (330 mL) aged between 20 and 30 years resulted in an uptake of 112 ng and 56 ng of melatonin for men and women, respectively. Melatonin bioavailability from beer was directly proportional to the dose, and serum analysis by ELISA prior and 45 min post-administration confirmed that melatonin increase in human serum was related to drinking melatonin-rich beer [162]. In humans, serum melatonin concentrations increase significantly from 10 to 12 pg/mL at 1 h after a single consumption of 100 mL red wine [80]. The “French paradox” (high long-life expectancy of the French people, despite its theoretically unhealthy diet rich in fat), associated with regular consumption of red wine, which includes plant polyphenols, especially resveratrol, may also be because of the intake of melatonin, which is present in red wine.

Fruits seem to be also a good source of phytomelatonin. Served to 12 healthy male volunteers for breakfast as either juice extracted from 1 kg of orange or pineapple or two whole bananas,
containing 302 ng, 150 ng, and 1.7 ng phytomelatonin, respectively, elevated the plasma melatonin levels, generating characteristic change kinetics over time [163]. A blood sample was collected from the experimental participants before breakfast (control), as well as 1, 2, and 3 h after consuming the fruit products. Serum melatonin concentration (assessed by ELISA) increased already at 1 h, reaching the highest values at the second hour after fruit consumption. The values were significantly increased for pineapples (146 vs. 48 pg/mL, \( p = 0.002 \)), oranges (151 vs. 40 pg/mL, \( p = 0.005 \)), and bananas (140 vs. 32 pg/mL, \( p = 0.008 \)), respectively. Between the second and third hours of the experiment, plasma melatonin levels decreased rapidly in all subjects, reaching values lower than 50 pg/mL after the third hour. In this experiment, serum antioxidant capacity (estimated by oxygen radical absorbance capacity (ORAC) and ferric reducing antioxidant power (FRAP) tests) following fruit consumption was also significantly elevated and was strongly correlated with serum melatonin concentration for all the three fruits tested [163].

Although many herbs containing significant melatonin amounts are known, except St. John’s wort, no study reported the oral bioavailability of melatonin from herbal products. The daily treatment of 13 healthy subjects for three weeks with a hydroethanolic extract of dried flowering tops or aerial parts of St. John’s wort significantly increased the nocturnal melatonin plasma concentration in these subjects [164]. However, this study was not very informative because the melatonin concentration in the extract, and the exact melatonin amount ingested from the plant product, was unknown. Conclusions were only based on the rise in plasma melatonin levels. Therefore, it is possible to infer that the incremental rise in melatonin levels may not have been linked to phytomelatonin intake from plant, but rather occurred as a result of some plant constituents that triggered the release of endogenous melatonin from the gut.

On the other hand, some authors criticized the studies investigating the measurement of blood and urine melatonin after the intake of foods containing this molecule, suggesting that the claimed increases in circulating melatonin are not consistent with the amount of dietary melatonin ingested [165,166]. However, after the administration of a glass of melatonin-enriched red wine, the serum melatonin levels changed, peaking at 60 min post-intake, supporting the role of absorbed dietary melatonin in counteracting the physiological decline of its endogenous levels in the bloodstream [89].

6. Conclusions

Therein, the use of dietary melatonin may be extremely beneficial in helping to maximize the health-promoting effects of medicinal plants and healthy foods in humans, possibly acting in synergy with other bioactive phytochemicals (i.e., polyphenols) that are ingested daily. However, the current lack of knowledge on the oral bioavailability of melatonin in the humans diet clearly indicates the need for more in-depth clinical trials, namely considering the circadian and seasonal variations of endogenous melatonin and allowing to estimate the amount of melatonin ingested. In fact, as there is no difference between endogenous and exogenously acquired melatonin, it is very difficult to assess the dietary contribution in humans.

Author Contributions: B.S., F.S., P.V.T.F., A.K., L.d.J., K.T., J.S.-R., M.M.P., M.M., N.M., M.I., contributed equally to this work. J.S.-R., M.M.P., N.M., and M.I. critically reviewed the manuscript. All the authors read and approved the final manuscript.

Funding: This research received no external funding.

Acknowledgments: N. Martins would like to thank the Portuguese Foundation for Science and Technology (FCT-Portugal) for the Strategic project ref. UID/BIM/04293/2013 and “NORTE2020—Northern Regional Operational Program” (NORTE-01-0145-FEDER-000012). M. Martorell would like to thank the support from CONICYT PIA/APOYO CCTE AFB170007.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Manchester, L.C.; Tan, D.-X.; Reiter, R.J.; Park, W.; Monis, K.; Qi, W. High levels of melatonin in the seeds of edible plants: Possible function in germ tissue protection. *Life Sci.* **2000**, *67*, 3023–3029. [CrossRef]

2. Lerner, A.B.; Case, J.D.; Takahashi, Y.; Lee, T.H.; Mori, W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. *J. Am. Chem. Soc.* **1958**, *80*, 2587. [CrossRef]

3. Conti, A.; Tettamanti, C.; Singaravel, M.; Haldar, C.; Pandi-Perumal, R.; Maestroni, G. Melatonin: An ubiquitous and evolutionary hormone. In *Treatise Pineal Gland Melatonin*; Science Publishers: Boca Raton, FL, USA, 2002; pp. 105–143.

4. Reiter, R.J.; Fraschini, F. Endocrine Aspects of the Mammalian Pineal Gland: A Review. *Neuroendocrinology* **1969**, *5*, 219–255. [CrossRef] [PubMed]

5. Hardeland, R. Ubiquitous melatonin-presence and effects in unicells, plants and animals. *Trends Comp. Biochem. Physiol.* **1996**, *2*, 25–45.

6. Vivien-Roels, B.; Pévet, P. Melatonin: Presence and formation in invertebrates. *Experientia* **1993**, *49*, 642–647. [CrossRef]

7. Poeggeler, B.; Balzer, I.; Fischer, J.; Behrmann, G.; Hardeland, R. A role of melatonin in dinoflagellates? *Eur. J. Endocrinol.* **1989**, *120*, S97. [CrossRef]

8. Balzer, I.; Hardeland, R. Photoperiodism and effects of indoleamines in a unicellular alga, *Gonyaulax polyedra*. *Science* **1991**, *253*, 795–797. [CrossRef]

9. Dubbels, R.; Reiter, R.; Klenke, E.; Goebel, A.; Schnakenberg, E.; Ehlers, C.; Schiwarra, H.; Schloot, W. Melatonin in edible plants identified by radioimmunoassay and by high performance liquid chromatography-mass spectrometry. *J. Pineal Res.* **1995**, *18*, 28–31. [CrossRef]

10. Hattori, A.; Migitaka, H.; Iigo, M.; Itoh, M.; Yamamoto, K.; Ohtani-Kaneko, R.; Hara, M.; Suzuki, T.; Reiter, R.J. Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. *Biochem. Mol. Biol. Int.* **1995**, *35*, 627–634.

11. Tan, D.-X.; Chen, L.D.; Poeggeler, B.; Manchester, L.C.; Reiter, R.J. Melatonin: A potent, endogenous hydroxyl radical scavenger. *Endocr J.* **1993**, *1*, 57–60.

12. Reiter, R.; Tan, D.; Mayo, J.; Sainz, R.; Leon, J.; Czarnocki, Z. Melatonin as an antioxidant: Biochemical mechanisms and pathophysiological implications in humans. *Acta Biochim. Pol.* **2003**, *50*, 1129–1146. [PubMed]

13. Reiter, R.J.; Mayo, J.C.; Tan, D.X.; Sainz, R.M.; Alatorre-Jimenez, M.; Qin, L. Melatonin as an antioxidant: Under promises but over delivers. *J. Pineal Res.* **2016**, *61*, 253–278. [CrossRef] [PubMed]

14. Reiter, R.; Tan, D.; Rosales-Corral, S.; Galano, A.; Zhou, X.; Xu, B. Mitochondria: Central organelles for melatonin’s antioxidant and anti-aging actions. *Molecules* **2018**, *23*, 509. [CrossRef] [PubMed]

15. Hardeland, R. Atioxidative protection by melatonin. *Endocrine* **2005**, *27*, 119–130. [CrossRef]

16. Hardeland, R.; Cardinale, D.P.; Srinivasan, V.; Spence, D.W.; Brown, G.M.; Pandi-Perumal, S.R. Melatonin—an pleiotropic, orchestrating regulator molecule. *Prog. Neurobiol.* **2011**, *93*, 350–384. [CrossRef]

17. Pandi-Perumal, S.R.; BaHammam, A.S.; Brown, G.M.; Spence, D.W.; Bharti, V.K.; Kaur, C.; Hardeland, R.; Cardinale, D.P. Melatonin antioxidative defense: Therapeutical implications for aging and neurodegenerative processes. *Neurotox. Res.* **2013**, *23*, 267–300. [PubMed]

18. Allegrà, M.; Reiter, R.; Tan, D.-X.; Gentile, C.; Tesoriere, L.; Livrea, M. The chemistry of melatonin’s interaction with reactive species. *J. Pineal Res.* **2003**, *34*, 1–10. [CrossRef]

19. Balabusta, M.; Szafrańska, K.; Posmyk, M.M. Exogenous melatonin improves antioxidant defense in cucumber seeds (*Cucumis sativus* L.) germinated under chilling stress. *Front. Plant Sci.* **2016**, *7*, 575.

20. Fischer, T.W.; Kleszczyński, K.; Hardkop, L.H.; Kruse, N.; Zilliken, D. Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVR-induced depletion, and protects against the formation of DNA damage (8-hydroxy-2’-deoxyguanosine) in ex vivo human skin. *J. Pineal Res.* **2013**, *54*, 303–312. [CrossRef]

21. Gütö, E.; Tan, D.X.; Reiter, R.J.; Karbownik, M.; Manchester, L.C.; Cuzzocrea, S.; Fulia, F.; Barberi, I. Individual and synergistic antioxidative actions of melatonin: Studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. *J. Pharm. Pharmacol.* **2001**, *53*, 1393–1401. [CrossRef]
22. Wang, P.; Yin, L.; Liang, D.; Li, C.; Ma, F.; Yue, Z. Delayed senescence of apple leaves by exogenous melatonin treatment: Toward regulating the ascorbate–glutathione cycle. *J. Pineal Res.* 2012, 53, 11–20. [CrossRef] [PubMed]

23. Szafranska, K.; Posmyk, M.M. Phytomelatonin physiological functions (Ch 5). In *Serotonin and Melatonin: Their Functional Role in Plants, Food, Phytomedicine, and Human Health*; Ravishankar, G.A., Ramakrishna, A., Eds.; CRC Press Taylor & Francis Group: Boca Raton, FL, USA, 2016; pp. 61–72.

24. Kołodzieczyk, J.; Balabusta, M.; Szewczyk, R.; Posmyk, M.M. The levels of melatonin and its metabolites in conditioned corn (*Zea mays L.*) and cucumber (*Cucumis sativus L.*) seeds during storage. *Acta Physiol. Plant.* 2015, 37, 105.

25. Tan, D.-X.; Manchester, L.C.; Di Mascio, P.; Martinez, G.R.; Prado, F.M.; Reiter, R.J. Novel rhythms of N1-acetyl-N2-formyl-5-methoxykynurenamine and its precursor melatonin in water hyacinth: Importance for phytoremediation. *FASEB J.* 2007, 21, 1724–1729. [CrossRef] [PubMed]

26. Rosen, J.; Than, N.N.; Koch, D.; Poeggeler, B.; Laatsch, H.; Hardeland, R. Interactions of melatonin and its metabolites with the ABTS cation radical: Extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. *J. Pineal Res.* 2006, 41, 374–381. [CrossRef] [PubMed]

27. Galano, A.; Tan, D.-X.; Reiter, R.J. On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK. *J. Pineal Res.* 2013, 54, 245–257. [CrossRef] [PubMed]

28. Arnao, M.B.; Hernández-Ruiz, J. The physiological function of melatonin in plants. *Plant. Signal. Behav.* 2006, 1, 89–95. [CrossRef] [PubMed]

29. Posmyk, M.M.; Janas, K.M. Melatonin in plants. *Acta Physiol. Plant.* 2009, 31, 1. [CrossRef]

30. Paredes, S.D.; Korkmaz, A.; Manchester, L.C.; Tan, D.-X.; Reiter, R.J. Phytomelatonin: A review. *J. Exp. Bot.* 2008, 60, 57–69. [CrossRef]

31. Tan, D.-X.; Hardeland, R.; Manchester, L.C.; Korkmaz, A.; Ma, S.; Rosales-Corral, S.; Reiter, R.J. Functional roles of melatonin in plants, and perspectives in nutritional and agricultural science. *J. Exp. Bot.* 2011, 63, 577–597. [CrossRef]

32. Arnao, M.B. Phytomelatonin: Discovery, content, and role in plants. *Adv. Bot.* 2014, 2014, 1–11. [CrossRef]

33. Erland, L.A.; Murch, S.J.; Reiter, R.J.; Saxena, P.K. A new balancing act: The many roles of melatonin and serotonin in plant growth and development. *Plant. Signal. Behav.* 2015, 10, e1096469. [CrossRef] [PubMed]

34. Hardeland, R. Melatonin in plants–diversity of levels and multiplicity of functions. *Front. Plant Sci.* 2016, 7, 198. [CrossRef] [PubMed]

35. Arnao, M.B.; Hernández-Ruiz, J. Melatonin promotes adventitious-and lateral root regeneration in etiolated hypocotyls of *Lupinus albus* L. *J. Pineal Res.* 2007, 42, 147–152. [CrossRef]

36. Hernández-Ruiz, J.; Arnao, M. Distribution of melatonin in different zones of lupin and barley plants at different ages in the presence and absence of light. *J. Agric. Food Chem.* 2008, 56, 10567–10573. [CrossRef] [PubMed]

37. Arnao, M.B.; Hernández-Ruiz, J. Assessment of different sample processing procedures applied to the determination of melatonin in plants. *Phytochem. Anal.* 2009, 20, 14–18. [CrossRef]

38. Chen, Q.; Qi, W.-b.; Reiter, R.J.; Wei, W.; Wang, B.-m. Exogenously applied melatonin stimulates root growth and raises endogenous indoleacetic acid in roots of etiolated seedlings of Brassica juncea. *J. Plant Physiol.* 2009, 166, 324–328. [CrossRef]

39. Zhang, N.; Zhang, H.J.; Zhao, B.; Sun, Q.Q.; Cao, Y.Y.; Li, R.; Wu, X.X.; Weeda, S.; Li, L.; Ren, S. The RNA-seq approach to discriminate gene expression profiles in response to melatonin on cucumber lateral root formation. *J. Pineal Res.* 2014, 56, 39–50. [CrossRef]

40. Ravishankar, G.A.; Ramakrishna, A. *Serotonin and Melatonin: Their Functional Role in Plants, Food, Phytomedicine, and Human Health*; CRC Press: Boca Raton, FL, USA, 2016.

41. Ramakrishna, A.; Giridhar, P.; Sankar, K.U.; Ravishankar, G.A. Melatonin and serotonin profiles in beans of Coffea species. *J. Pineal Res.* 2012, 52, 470–476. [CrossRef]

42. Padumanonda, T.; Johns, J.; Sangkasat, A.; Tiwaworanant, S. Determination of melatonin content in traditional Thai herbal remedies used as sleeping aids. *Daru J. Pharm. Sci.* 2014, 22, 6. [CrossRef]

43. Chen, G.; Huo, Y.; Tan, D.-X.; Liang, Z.; Zhang, W.; Zhang, Y. Melatonin in Chinese medicinal herbs. *Life Sci.* 2003, 73, 19–26. [CrossRef]
44. Reiter, R.J.; Manchester, L.C.; Tan, D.-X. Melatonin in walnuts: Influence on levels of melatonin and total antioxidant capacity of blood. *Nutrition* 2005, 21, 920–924. [CrossRef] [PubMed]

45. Zhao, Y.; Tan, D.X.; Lei, Q.; Chen, H.; Wang, L.; Li, Q.; Gao, Y.; Kong, J. Melatonin and its potential biological functions in the fruits of sweet cherry. *J. Pineal Res.* 2013, 55, 79–88. [CrossRef] [PubMed]

46. Burkhardt, S.; Tan, D.-X.; Manchester, L.C.; Hardeland, R.; Reiter, R.J. Detection and quantification of the antioxidant melatonin in Montmorency and Balaton tart cherries (*Prunus cerasus*). *J. Agric. Food Chem.* 2001, 49, 4898–4902. [CrossRef] [PubMed]

47. Vitalini, S.; Gardana, C.; Zanzotto, A.; Simonetti, P.; Faoro, F.; Fico, G.; Iriti, M. The presence of melatonin in grapevine (*Vitis vinifera L.*) berry tissues. *J. Pineal Res.* 2011, 51, 331–337. [CrossRef] [PubMed]

48. Stürtz, M.; Cerezo, A.B.; Cantos-Villar, E.; García-Parrilla, M. Determination of the melatonin content of different varieties of tomatoes (*Lycopersicon esculentum*) and strawberries (*Fragaria ananassa*). *Food Chem.* 2011, 127, 1329–1334.

49. Mena, P.; Gil-Izquierdo, Á.; Moreno, D.A.; Martí, N.; García-Viguera, C. Assessment of the melatonin production in pomegranate wines. *LWT-Food Sci. Technol.* 2012, 47, 13–18. [CrossRef]

50. Murch, S.J.; Simmons, C.B.; Saxena, P.K. Melatonin in feverfew and other medicinal plants. *Lancet* 1997, 350, 1598–1599. [CrossRef]

51. Okazaki, M.; Ezura, H. Profiling of melatonin in the model tomato (*Solanum lycopersicum L.*) cultivar Micro-Tom. *J. Pineal Res.* 2009, 46, 338–343. [CrossRef]

52. Stege, P.W.; Sombra, L.L.; Messina, G.; Martinez, L.D.; Silva, M.F. Determination of melatonin in wine and plant extracts by capillary electrophromatography with immobilized carboxylic multi-walled carbon nanotubes as stationary phase. *Electrophoresis* 2010, 31, 2242–2248. [CrossRef]

53. Park, S.; Lee, D.E.; Jang, H.; Byeon, Y.; Kim, Y.S.; Back, K. Melatonin-rich transgenic rice plants exhibit resistance to herbicide-induced oxidative stress. *J. Pineal Res.* 2013, 54, 258–263. [CrossRef]

54. Bajwa, V.S.; Shukla, M.R.; Sherif, S.M.; Murch, S.J.; Saxena, P.K. Role of melatonin in alleviating cold stress in Arabidopsis thaliana. *J. Pineal Res.* 2014, 56, 238–245. [CrossRef] [PubMed]

55. Zhang, N.; Sun, Q.; Zhang, H.; Cao, Y.; Weeda, S.; Ren, S.; Guo, Y.-D. Roles of melatonin in abiotic stress resistance in plants. *J. Exp. Bot.* 2014, 66, 647–656. [CrossRef] [PubMed]

56. Shi, H.; Chen, K.; Wei, Y.; He, C. Fundamental issues of melatonin-mediated stress signaling in plants. *Front. Plant Sci.* 2016, 7, 1124. [CrossRef] [PubMed]

57. Janas, K.M.; Posmyk, M.M. Melatonin, an underestimated natural substance with great potential for agricultural application. *Acta Physiol. Plant.* 2013, 35, 3285–3292. [CrossRef]

58. Kołodziejczyk, I.; Posmyk, M.M. Melatonin—a new plant biostimulator? *J. Elem.* 2016, 21, 1187–1198. [CrossRef]

59. Lazar, D.; Murch, S.J.; Beilby, M.J.; Al Khazaaly, S. Exogenous melatonin affects photosynthesis in characeae Chara australis. *Plant. Signal. Behav.* 2013, 8, e23279. [CrossRef] [PubMed]
67. Szafranska, K.; Reiter, R.J.; Posmyk, M.M. Melatonin application to Pismum sativum L. seeds positively influences the function of the photosynthetic apparatus in growing seedlings during paraquat-induced oxidative stress. *Front. Plant Sci.* 2016, 7, 1663.

68. Arnao, M.B.; Hernandez-Ruiz, J. Protective effect of melatonin against chlorophyll degradation during the senescence of barley leaves. *J. Pineal Res.* 2009, 46, 58–63. [CrossRef] [PubMed]

69. Szafranska, K.; Reiter, R.J.; Posmyk, M.M. Melatonin improves the photosynthetic apparatus in pea leaves stressed by paraquat via chlorophyll breakdown regulation and its accelerated de novo synthesis. *Front. Plant Sci.* 2017, 8, 878. [CrossRef] [PubMed]

70. Wang, P.; Sun, X.; Chang, C.; Feng, F.; Liang, D.; Cheng, L.; Ma, F. Delay in leaf senescence of Malus hupehensis by long-term melatonin application is associated with its regulation of metabolic status and protein degradation. *J. Pineal Res.* 2013, 55, 424–434. [PubMed]

71. Wang, P.; Sun, X.; Xie, Y.; Li, M.; Chen, W.; Zhang, S.; Liang, D.; Ma, F. Melatonin regulates proteomic changes during leaf senescence in Malus hupehensis. *J. Pineal Res.* 2014, 57, 291–307. [CrossRef] [PubMed]

72. Li, C.; Tan, D.-X.; Liang, D.; Chang, C.; Jia, D.; Ma, F. Melatonin mediates the regulation of ABA metabolism, free-radical scavenging, and stomatal behaviour in two Malus species under drought stress. *J. Exp. Bot.* 2014, 66, 669–680. [CrossRef]

73. Meng, J.F.; Xu, T.F.; Wang, Z.Z.; Fang, Y.L.; Xi, Z.M.; Zhang, Z.W. The ameliorative effects of melatonin on grape cuttings under water-deficient stress: Antioxidant metabolites, leaf anatomy, and chloroplast morphology. *J. Pineal Res.* 2014, 57, 200–212. [CrossRef]

74. Kołodziejczyk, I.; Dzitko, K.; Szewczyk, R.; Posmyk, M.M. Exogenous melatonin improves corn (Zea mays L.) embryo proteome in seeds subjected to chilling stress. *J. Plant Physiol.* 2016, 193, 47–56.

75. Kołodziejczyk, I.; Dzitko, K.; Szewczyk, R.; Posmyk, M.M. Exogenous melatonin expediently modifies proteome of maize (Zea mays L.) embryo during seed germination. *Acta Physiol. Plant.* 2016, 38, 146.

76. Najeeb, S.; Khurshid, Z.; Zohaib, S.; Zafar, M.S. Therapeutic potential of melatonin in oral medicine and periodontology. *J. Pineal Res.* 2012, 55, 291–307. [CrossRef] [PubMed]

77. Lee, H.Y.; Byeon, Y.; Back, K. Melatonin as a signal molecule triggering defense responses against pathogen attack in Arabidopsis and tobacco. *J. Pineal Res.* 2014, 57, 262–268. [CrossRef]

78. Arnao, M.B.; Hernandez-Ruiz, J. Melatonin: Plant growth regulator and/or biostimulator during stress? *Trends Plant Sci.* 2014, 19, 789–797. [CrossRef]

79. Park, W.J. Melatonin as an endogenous plant regulatory signal: Debates and perspectives. *J. Plant Biol.* 2011, 54, 143–149. [CrossRef]

80. Iriti, M.; Varoni, E.M.; Vitalini, S. Melatonin in traditional Mediterranean diets. *J. Pineal Res.* 2010, 49, 101–105. [CrossRef]

81. Pfeffer, M.; Korf, H.W.; Wicht, H. Synchronizing effects of melatonin on diurnal and circadian rhythms. *Gen. Comp. Endocrinol.* 2018, 258, 215–221. [CrossRef] [PubMed]

82. Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P. *Molecular Biology of the Cell*, 5th ed.; Garland Science: New York, NY, USA, 2008; p. 1616.

83. Radogna, F.; Diederich, M.; Ghibelli, L. Melatonin: A pleiotropic molecule regulating inflammation. *Biochem. Pharmacol.* 2010, 80, 1844–1852. [CrossRef] [PubMed]

84. Pandi-Perumal, S.R.; Zisapel, N.; Srinivasan, V.; Cardinalli, D.P. Melatonin and sleep in aging population. *Expert Opin. Pharmacother.* 2005, 6, 911–925. [CrossRef]

85. Cardinalli, D.P.; Pagano, E.S.; Bernasconi, P.S.; Reynoso, R.; Scacchi, P. Melatonin and mitochondrial dysfunction in the central nervous system. *Horm. Behav.* 2013, 63, 322–330. [CrossRef]

86. Cruz, M.H.C.; Leal, C.L.V.; Cruz, J.F.; Tan, D.-X.; Reiter, R.J. Essential actions of melatonin in protecting the ovary from oxidative damage. *Theriogenology* 2014, 82, 925–932. [CrossRef]

87. Shen, Y.X.; Xu, S.Y.; Wei, W.; Sun, X.X.; Liu, L.H.; Yang, J.; Dong, C. The protective effects of melatonin from oxidative damage induced by amyloid beta-peptide 25–35 in middle-aged rats. *J. Pineal Res.* 2002, 32, 85–89. [CrossRef] [PubMed]

88. Dies, H.; Cheung, B.; Tang, J.; Rheinstäder, M.C. The organization of melatonin in lipid membranes. *Biochim. Biophys. Acta* 2015, 1848, 1032–1040. [CrossRef] [PubMed]

89. Iriti, M.; Varoni, E.M. The good health of Bacchus: Melatonin in grapes, the unveiled myth. *LWT-Food Sci. Technol.* 2016, 65, 758–761. [CrossRef]
90. Pandi-Perumal, S.R.; Srinivasan, V.; Maestroni, G.J.; Cardinali, D.P.; Poeggeler, B.; Hardeland, R. Melatonin: Nature’s most versatile biological signal? FEBS J. 2006, 273, 2813–2838. [CrossRef] [PubMed]

91. Vielma, J.R.; Bonilla, E.; Bonilla, L.C.; Mora, M.; Leendertz, S.M.; Bravoa, Y. Effects of melatonin on oxidative stress, and resistance to bacterial, parasitic, and viral infections: A review. Acta Trop. 2014, 137, 31–38. [CrossRef] [PubMed]

92. Andersen, L.P.; Gogenur, I.; Rosenberg, J.; Reiter, R.J. The Safety of Melatonin in Humans. Clin. Drug Investig. 2016, 36, 169–175. [CrossRef] [PubMed]

93. Pandi-Perumal, S.R.; Trakht, I.; Srinivasan, V.; Spence, D.; Maestroni, G.; Zisapel, N.; Cardinali, D.P. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. 2008, 85, 335–353. [CrossRef] [PubMed]

94. Borjigin, J.; Zhang, L.S.; Calinescu, A.A. Circadian regulation of pineal gland rhythmicity. Mol. Cell. Endocrinol. 2012, 349, 13–19. [CrossRef]

95. Arendt, J.; Broadway, J. Light and melatonin as zeitgebers in man. Chronobiol. Int. 1987, 4, 273–282. [CrossRef] [PubMed]

96. Sallinen, P.; Mänttäri, S.; Leskinen, H.; Vakkuri, O.; Ruskoaho, H.; Saarela, S. Long-term postinfarction melatonin administration alters the expression of DHPR, RyR2, SERCA2, and MT2 and elevates the ANP level in the rat left ventricle. J. Pineal Res. 2008, 45, 61–69. [CrossRef]

97. Singh, M.; Jadhav, H.R. Melatonin: Functions and ligands. Drug Discov. Today 2014, 19, 1411–1418. [CrossRef] [PubMed]

98. Turek, F.W.; Gillette, M.U. Melatonin, sleep, and circadian rhythms: Rationale for development of specific melatonin agonists. Sleep Med. 2004, 5, 523–532. [CrossRef] [PubMed]

99. Lamont, K.; Nduhirabandi, F.; Adam, T.; Thomas, D.P.; Opie, L.H.; Lecour, S. Role of melatonin, melatonin receptors and STAT3 in the cardioprotective effect of chronic and moderate consumption of red wine. Biochem. Biophys. Res. Commun. 2015, 465, 719–724. [CrossRef] [PubMed]

100. Slominski, R.M.; Reiter, R.J.; Schlabritz-Loutsevitch, N.; Ostrom, R.S.; Slominski, A.T. Melatonin membrane receptors in peripheral tissues: Distribution and functions. Mol. Cell. Endocrinol. 2012, 351, 152–166. [CrossRef] [PubMed]

101. Hardeland, R. Melatonin and retinoid orphan receptors: Demand for new interpretations after their exclusion as nuclear melatonin receptors. Melatonin Res. 2018, 1, 78–93. [CrossRef]

102. Ekmeckioglu, C. Melatonin receptors in humans: Biological role and clinical relevance. Biomed. Pharmacother. 2006, 60, 97–108. [CrossRef] [PubMed]

103. Drew, J.E.; Barrett, P.; Mercer, J.G.; Canet, E.; Delagrange, P. Localization of the melatonin-related receptor in the rodent brain and peripheral tissues. J. Neuroendocr. 2001, 13, 453–458. [CrossRef]

104. Shu, T.; Wu, T.; Pang, M.; Liu, C.; Wang, X.; Wang, J.; Liu, B.; Rong, L. Effects and mechanisms of melatonin on neural differentiation of induced pluripotent stem cells. Biochem. Biophys. Res. Commun. 2016, 474, 566–571. [CrossRef]

105. Favero, G.; Moretti, E.; Bonomini, F.; Reiter, R.J.; Rodella, L.F.; Rezzani, R. Promising Antineoplastic Actions of Melatonin. Front. Pharmacol. 2018, 9, 1086. [CrossRef] [PubMed]

106. Vriend, J.; Reiter, R.J. Melatonin, bone regulation and the ubiquitin-proteasome connection: A review. Life Sci. 2016, 145, 152–160. [CrossRef]

107. Li, C.; Zhou, X. Melatonin and male reproduction. Clin. Chin. Acta Int. J. Clin. Chem. 2015, 446, 175–180. [CrossRef] [PubMed]

108. Zhang, Y.; Li, W.; Ma, Y.; Wang, D.; Zhao, X.; Zeng, C.; Zhang, M.; Zeng, X.; Meng, Q.; Zhou, G. Improved development by melatonin treatment after vitrification of mouse metaphase II oocytes. Cryobiology 2016, 73, 335–342. [CrossRef] [PubMed]

109. Gupta, T.; Sahni, D.; Gupta, R.; Gupta, S.K. Expanding the horizons of melatonin use: An immunohistochemical neuroanatomic distribution of MT1 and MT2 receptors in human brain and retina. J. Anat. Soc. India 2017, 192, 9–18. [CrossRef]

110. Dominguez-Rodriguez, A.; Abreu-Gonzalez, P.; Jose, M.; Consuegra-Sanchez, L.; Piccolo, R.; Gonzalez-Gonzalez, J.; Garcia-Camarero, T.; del Mar Garcia-Saiz, M.; Aldea-Perona, A.; Reiter, R.J. Usefulness of early treatment with melatonin to reduce infarct Size in patients with ST-segment elevation myocardial infarction receiving percutaneous coronary intervention (from the Melatonin Adjunct in the Acute Myocardial Infarction Treated With Angioplasty Trial). Am. J. Cardiol. 2017, 120, 522–526. [PubMed]
132. Koziróg, M.; Poliwczak, A.R.; Duchnowicz, P.; Koter-Michalak, M.; Sikora, J.; Broncel, M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. *J. Pineal Res.* 2010, 50, 261–266. [CrossRef] [PubMed]

133. Gomes, A.L.; Hermsdorff, H.H.M.; Bressan, J. Melatonin intake and potential chronobiological effects on human health. *Crit. Rev. Food Sci. Nutr.* 2017, 133–140. [CrossRef]

134. Slominski, A.T.; Zmijewski, M.A.; Semak, I.; Kim, T.-K.; Janjetovic, Z.; Slominski, R.M.; Zmijewski, J.W. Antioxidative defense system: Reactions and products. *Neurosignals* 2000, 31, 284–290. [CrossRef]

135. El-Shenawy, S.M.; Abdel-Salam, O.M.; Baiuomy, A.R.; El-Batran, S.; Arbid, M.S. Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. *Pharmacol. Res.* 2002, 46, 235–243. [CrossRef]

136. Pugazhenthhi, K.; Kapoor, M.; Clarkson, A.N.; Hall, I.; Appleton, I. Melatonin accelerates the process of wound repair in full-thickness incisional wounds. *J. Pineal Res.* 2008, 44, 387–396. [CrossRef]

137. Weishaupt, J.H.; Bartels, C.; Pölking, E.; Dietrich, J.; Rohde, G.; Poeggeler, B.; Sperling, S.; Bohn, M.; Hüther, G. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. *J. Pineal Res.* 2006, 41, 313–323. [CrossRef] [PubMed]

138. Zaslavskaia, R.; Shcherbakov, E.; Logvinenko, S. Evaluation of different methods of treatment of patients with stable stenocardia combined with arterial hypertension according to echocardiographic data. *Klin. Meditsina* 2010, 85, 40–43.

139. Thomale, U.-W.; Griebelow, M.; Kroppenstedt, S.-N.; Unterberg, A.W.; Stover, J.F. Small volume resuscitation with HyperHaes™ improves pericontusional perfusion and reduces lesion volume following controlled cortical impact injury in rats. *J. Neurotrauma* 2004, 21, 1737–1746. [CrossRef] [PubMed]

140. Traystman, R.J.; Kirsch, J.R.; Koehler, R.C. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. *J. Appl. Physiol.* 1991, 71, 1185–1195. [CrossRef] [PubMed]

141. Wakatsuki, A.; Okatani, Y.; Shinohara, K.; Ikenoue, N.; Kaneda, N.; Fukaya, T. Melatonin protects fetal rat brain against oxidative mitochondrial damage. *J. Pineal Res.* 2001, 30, 22–28. [CrossRef] [PubMed]

142. Tengattini, S.; Reiter, R.J.; Tan, D.X.; Terron, M.P.; Rodella, L.F.; Rezzani, R. Cardiovascular diseases: Protective effects of melatonin. *J. Pineal Res.* 2008, 44, 16–25. [CrossRef] [PubMed]

143. Tan, D.-X.; Manchester, L.C.; Reiter, R.J.; Qi, W.-B.; Korbownik, M.; Calvo, J.R. Significance of melatonin in antioxidative defense system: Reactions and products. *Neurosignals* 2000, 9, 137–159. [CrossRef] [PubMed]

144. Slominski, A.T.; Zmijewski, M.A.; Semak, I.; Kim, T.-K.; Janjetovic, Z.; Slominski, R.M.; Zmijewski, J.W. Melatonin, mitochondria, and the skin. *Cell. Mol. Life Sci.* 2017, 74, 3913–3925. [CrossRef] [PubMed]

145. Shen, Y.; Zhang, G.; Liu, L.; Xu, S. Suppressive effects of melatonin on amyloid-β-induced glial activation in rat hippocampus. *Arch. Med. Res.* 2007, 38, 284–290. [CrossRef]

146. Ren, W.; Wang, P.; Yan, J.; Liu, G.; Zeng, B.; Hussain, T.; Peng, C.; Yin, J.; Li, T.; Wei, H. Melatonin alleviates weanling stress in mice: Involvement of intestinal microbiota. *J. Pineal Res.* 2018, 64, e12448. [CrossRef]

147. Reiter, R.J.; Tan, D.-X. Melatonin: A novel protective agent against oxidative injury of the ischemic/reperfused heart. *Cardiovasc. Res.* 2003, 58, 10–19. [CrossRef]

148. Grossman, E.; Laudon, M.; Yalcin, R.; Zengil, H.; Peleg, E.; Sharabi, Y.; Kamari, Y.; Shen-Orr, Z.; Zisapel, N. Melatonin reduces night blood pressure in patients with nocturnal hypertension. *Am. J. Med.* 2006, 119, 898–902. [CrossRef] [PubMed]

149. Dwaich, K.H.; Al-Amran, F.G.; Al-Sheibani, B.I.; Al-Aubaidy, H.A. Melatonin effects on myocardial ischemia-reperfusion injury: Impact on the outcome in patients undergoing coronary artery bypass grafting surgery. *Int. J. Cardiol.* 2016, 221, 977–986. [CrossRef] [PubMed]

150. Gubin, D.G.; Gubin, G.D.; Gapon, L.I.; Weinert, D. Daily Melatonin Administration Attenuates Age-Dependent Disturbances of Cardiovascular Rhythms. *Curr. Aging Sci.* 2016, 9, 5–13. [CrossRef] [PubMed]

151. Naseem, M.; Parvez, S. Role of melatonin in traumatic brain injury and spinal cord injury. *Sci. World J.* 2014, 2014, 1–13. [CrossRef] [PubMed]

152. Kilic, E.; Kilic, Ü.; Bacigaluppi, M.; Guo, Z.; Abdallah, N.B.; Wolfer, D.P.; Reiter, R.J.; Hermann, D.M.; Bassetti, C.L. Delayed melatonin administration promotes neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after mild focal cerebral ischemia in mice. *J. Pineal Res.* 2008, 45, 142–148. [CrossRef] [PubMed]
153. Therapeutic Goods Administration. *Australian Public Assessment Report for Melatonin*; RAD Data Australia Pty Ltd.: Melbourne, VIC, Australia, 2009.

154. Ng, K.Y.; Leong, M.K.; Liang, H.; Paxinos, G. Melatonin receptors: Distribution in mammalian brain and their respective putative functions. *Brain Struct. Funct.* 2017, 222, 2921–2939. [CrossRef]

155. Blask, D.E.; Dauchy, R.T.; Sauer, L.A.; Krause, J.A. Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: Melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. *Carcinogenesis* 2004, 25, 951–960.

156. Lee, B.-J.; Parrott, K.A.; Ayres, J.W. Development and characterization of an oral controlled-release delivery system for melatonin. *Drug Dev. Ind. Pharm.* 1996, 22, 269–274. [CrossRef]

157. Yeleswaram, K.; McLaughlin, L.G.; Knipe, J.O.; Schabdach, D. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. *J. Pineal Res.* 1997, 22, 45–51. [CrossRef]

158. Neddegaard, F.; Kennaway, D.J. A method of achieving physiological plasma levels of melatonin in the chicken by oral administration. *J. Pineal Res.* 1999, 27, 129–138. [CrossRef]

159. Reiter, R.J.; Tana, D.-X.; Manchester, L.C.; Simopoulos, A.P.; Maldonado, M.D.; Floresa, L.J.; Terron, M.P. Melatonin in Edible Plants (Phytomelatonin): Identification, Concentrations, Bioavailability and Proposed Functions. *World Rev. Nutr. Diet.* 2007, 97, 211–230. [PubMed]

160. Aguilera, Y.; Rebollo-Hernanz, M.; Herrera, T.; Cayuelas, L.T.; Rodriguez-Rodriguez, P.; de Pablo, A.L.L.; Arribas, S.M.; Martin-Cabrejas, M.A. Intake of bean sprouts influences melatonin and antioxidant capacity biomarker levels in rats. *Food Funct.* 2016, 7, 1438–1445. [CrossRef] [PubMed]

161. Andersen, L.P.; Werner, M.U.; Rosenkilde, M.M.; Harpsøe, N.G.; Fuglsang, H.; Rosenberg, J.; Gögenur, I. Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. *BMC Pharmacol. Toxicol.* 2016, 17, 8. [CrossRef] [PubMed]

162. Maldonado, M.D.; Moreno, H.; Calvo, J.R. Melatonin present in beer contributes to increase the levels of melatonin and antioxidant capacity of the human serum. *Clin. Nutr.* 2009, 28, 188–191. [CrossRef] [PubMed]

163. Sae-Teaw, M.; Johns, J.; Johns, N.P.; Subongkot, S. Serum melatonin levels and antioxidant capacities after consumption of pineapple, orange, or banana by healthy male volunteers. *J. Pineal Res.* 2013, 55, 58–64. [CrossRef] [PubMed]

164. WHO. *WHO Monographs on Selected Medicinal Plants*; World Health Organization: Geneva, Switzerland, 1999.

165. Iriti, M.; Varoni, E.M. Commentary: Are the proposed benefits of melatonin-rich foods too hard to swallow? *Front. Nutr.* 2016, 3, 2. [CrossRef]

166. Kennaway, D.J. Are the proposed benefits of melatonin-rich foods too hard to swallow? *Crit. Rev. Food Sci. Nutr.* 2017, 57, 958–962. [CrossRef]